

# Reena S Cecchini

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/6738471/reena-s-cecchini-publications-by-citations.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

31  
papers

3,906  
citations

19  
h-index

32  
g-index

32  
ext. papers

4,505  
ext. citations

7.5  
avg, IF

4.11  
L-index

#	Paper	IF	Citations
31	Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. <i>JAMA - Journal of the American Medical Association</i> , <b>2006</b> , 295, 2727-41	27.4	1241
30	Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. <i>Journal of the National Cancer Institute</i> , <b>2005</b> , 97, 1652-62	9.7	998
29	Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing breast cancer. <i>Cancer Prevention Research</i> , <b>2010</b> , 3, 696-706	3.2	473
28	Neurotoxicity from oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: NSABP C-07. <i>Journal of Clinical Oncology</i> , <b>2007</b> , 25, 2205-11	2.2	173
27	Long-term primary results of accelerated partial breast irradiation after breast-conserving surgery for early-stage breast cancer: a randomised, phase 3, equivalence trial. <i>Lancet, The</i> , <b>2019</b> , 394, 2155-2164 <sup>40</sup>		152
26	Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial. <i>Lancet, The</i> , <b>2016</b> , 387, 849-56	4.0	111
25	Menstrual history and quality-of-life outcomes in women with node-positive breast cancer treated with adjuvant therapy on the NSABP B-30 trial. <i>Journal of Clinical Oncology</i> , <b>2011</b> , 29, 1110-6	2.2	89
24	Amenorrhea in premenopausal women on the doxorubicin-and-cyclophosphamide-followed-by-docetaxel arm of NSABP B-30 trial. <i>Breast Cancer Research and Treatment</i> , <b>2009</b> , 113, 315-20	4.4	82
23	Body mass index and the risk for developing invasive breast cancer among high-risk women in NSABP P-1 and STAR breast cancer prevention trials. <i>Cancer Prevention Research</i> , <b>2012</b> , 5, 583-92	3.2	80
22	NSABP B-47/NRG Oncology Phase III Randomized Trial Comparing Adjuvant Chemotherapy With or Without Trastuzumab in High-Risk Invasive Breast Cancer Negative for HER2 by FISH and With IHC 1+ or 2. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 444-453	2.2	76
21	Long-term neurotoxicity effects of oxaliplatin added to fluorouracil and leucovorin as adjuvant therapy for colon cancer: results from National Surgical Adjuvant Breast and Bowel Project trials C-07 and LTS-01. <i>Cancer</i> , <b>2012</b> , 118, 5614-22	6.4	60
20	Quality of life in operable colon cancer patients receiving oral compared with intravenous chemotherapy: results from National Surgical Adjuvant Breast and Bowel Project Trial C-06. <i>Journal of Clinical Oncology</i> , <b>2007</b> , 25, 424-30	2.2	55
19	Patient-reported outcomes with anastrozole versus tamoxifen for postmenopausal patients with ductal carcinoma in situ treated with lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial. <i>Lancet, The</i> , <b>2016</b> , 387, 857-65	4.0	53
18	25-Hydroxy vitamin-D, obesity, and associated variables as predictors of breast cancer risk and tamoxifen benefit in NSABP-P1. <i>Breast Cancer Research and Treatment</i> , <b>2012</b> , 133, 1077-88	4.4	44
17	Long-Term Follow-Up of Cardiac Function and Quality of Life for Patients in NSABP Protocol B-31/NRG Oncology: A Randomized Trial Comparing the Safety and Efficacy of Doxorubicin and Cyclophosphamide (AC) Followed by Paclitaxel With AC Followed by Paclitaxel and Trastuzumab in Patients with Node-Positive Breast Cancer with Tamoxifen Compared with Human Endometrial Growth	2.2	39
16	Gynecologic conditions in participants in the NSABP breast cancer prevention study of tamoxifen and raloxifene (STAR). <i>American Journal of Obstetrics and Gynecology</i> , <b>2011</b> , 205, 535.e1-5	6.4	38
15	Body Mass Index at Diagnosis and Breast Cancer Survival Prognosis in Clinical Trial Populations from NRG Oncology/NSABP B-30, B-31, B-34, and B-38. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2016</b> , 25, 51-9	4	25

14	The use of tamoxifen and raloxifene for the prevention of breast cancer. <i>Recent Results in Cancer Research</i> , <b>2009</b> , 181, 113-9	1.5	24
13	An association between postoperative radiotherapy for primary breast cancer in 11 National Surgical Adjuvant Breast and Bowel Project (NSABP) studies and the subsequent appearance of pleural mesothelioma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , <b>2007</b> , 30, 294-6	2.7	21
12	Adolescents' experiences using the contraceptive patch versus pills. <i>Journal of Pediatric and Adolescent Gynecology</i> , <b>2011</b> , 24, 197-203	2	16
11	Baseline mammographic breast density and the risk of invasive breast cancer in postmenopausal women participating in the NSABP study of tamoxifen and raloxifene (STAR). <i>Cancer Prevention Research</i> , <b>2012</b> , 5, 1321-9	3.2	16
10	A pooled analysis of the cardiac events in the trastuzumab adjuvant trials. <i>Breast Cancer Research and Treatment</i> , <b>2020</b> , 179, 161-171	4.4	16
9	Primary results, NRG Oncology/NSABP B-35: A clinical trial of anastrozole (A) versus tamoxifen (tam) in postmenopausal patients with DCIS undergoing lumpectomy plus radiotherapy.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, LBA500-LBA500	2.2	8
8	Recruitment practices for U.S. minority and underserved populations in NRG oncology: Results of an online survey. <i>Contemporary Clinical Trials Communications</i> , <b>2018</b> , 10, 100-104	1.8	4
7	Final updated results of the NRG Oncology/NSABP Protocol P-2: Study of Tamoxifen and Raloxifene (STAR) in preventing breast cancer.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 1500-1500	2.2	4
6	Antimullerian Hormone as a Serum Biomarker for Risk of Chemotherapy-Induced Amenorrhea. <i>Journal of the National Cancer Institute</i> , <b>2021</b> , 113, 1105-1108	9.7	3
5	Meta-analysis of the cardiac events in the adjuvant trastuzumab trials.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 10066-10066	2.2	2
4	NRG Oncology/NSABP B-47 menstrual history study: impact of adjuvant chemotherapy with and without trastuzumab. <i>Npj Breast Cancer</i> , <b>2021</b> , 7, 55	7.8	1
3	Toxicity Index, Patient-Reported Outcomes, and Early Discontinuation of Endocrine Therapy for Breast Cancer Risk Reduction in NRG Oncology/NSABP B-35. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 3800-3812 <sup>2,3</sup>	3812 <sup>1</sup>	
2	Primary results, NRG Oncology/NSABP B-35: A clinical trial of anastrozole (A) versus tamoxifen (tam) in postmenopausal patients with DCIS undergoing lumpectomy plus radiotherapy.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, LBA500-LBA500	2.2	
1	Abstract P1-07-04: Potential role of the antibody-dependent cellular phagocytosis (ADCP) in tumors achieving pCR in NRG Oncology/NSABP B-52. <i>Cancer Research</i> , <b>2022</b> , 82, P1-07-04-P1-07-04	10.1	